The Parasite Reduction Ratio (PRR) Assay Version 2: Standardized Assessment of Plasmodium falciparum Viability after Antimalarial Treatment In Vitro
Authors:
- Annabelle WalzAWAnnabelle Walz
- Maëlle DuffeyMDMaëlle Duffey
- Ghaith AljayyoussiGAGhaith Aljayyoussi
- Sibylle SaxSSSibylle Sax
- Didier LeroyDLDidier Leroy
- Dominique BessonDBDominique Besson
- Jeremy N. BurrowsJBJeremy N. Burrows
- Mohammed H. Cherkaoui-RbatiMCMohammed H. Cherkaoui-Rbati
- Nathalie GobeauNGNathalie Gobeau
- Marie-Anne WestwoodMWMarie-Anne Westwood
- Christoph SiethoffCSChristoph Siethoff
- Francisco-Javier GamoFGFrancisco-Javier Gamo
Open Access
- 23 January 2023
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (2) , 163
Abstract
With artemisinin-resistant Plasmodium falciparum parasites emerging in Africa, the need for new antimalarial chemotypes is persistently high. The ideal pharmacodynamic parameters of a candidate drug are a rapid onset of action and a fast rate of parasite killing or clearance. To determine these parameters, it is essential to discriminate viable from nonviable parasites, which is complicated by the fact that viable parasites can be metabolically inactive, whilst dying parasites can still be metabolically active and morphologically unaffected. Standard growth inhibition assays, read out via microscopy or [3H] hypoxanthine incorporation, cannot reliably discriminate between viable and nonviable parasites. Conversely, the in vitro parasite reduction ratio (PRR) assay is able to measure viable parasites with high sensitivity. It provides valuable pharmacodynamic parameters, such as PRR, 99.9% parasite clearance time (PCT99.9%) and lag phase. Here we report the development of the PRR assay version 2 (V2), which comes with a shorter assay duration, optimized quality controls and an objective, automated analysis pipeline that systematically estimates PRR, PCT99.9% and lag time and returns meaningful secondary parameters such as the maximal killing rate of a drug (Emax) at the assayed concentration. These parameters can be fed directly into pharmacokinetic/pharmacodynamic models, hence aiding and standardizing lead selection, optimization, and dose prediction.Keywords
Funding Information
- R. Geigy Foundation (INV-007155/19-BMGF-006)
- Bill and Melinda Gates Foundation (INV-007155/19-BMGF-006)
This publication has 30 references indexed in Scilit:
- P. falciparum In Vitro Killing Rates Allow to Discriminate between Different Antimalarial Mode-of-ActionPLOS ONE, 2012
- The Activities of Current Antimalarial Drugs on the Life Cycle Stages of Plasmodium: A Comparative Study with Human and Rodent ParasitesPLOS Medicine, 2012
- Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimatorMalaria Journal, 2011
- The parasite clearance curveMalaria Journal, 2011
- In vitro and in vivo interaction of synthetic peroxide RBx11160 (OZ277) with piperaquine in Plasmodium modelsExperimental Parasitology, 2007
- Viable counts, characteristic evaluation for commercial lactic acid bacteria productsFood Microbiology, 2006
- Direct Recovery of Herpes Simplex Virus (HSV)-Specific T Lymphocyte Clones from Recurrent Genital HSV-2 LesionsThe Journal of Infectious Diseases, 1994
- A comparison of three methods of estimating EC50 in studies of drug resistance of malaria parasitesActa Tropica, 1993
- Clonal viability measurements on Plasmodium falciparum to assess in vitro schizonticidal activity of leupeptin, chloroquine, and 5-fluoroorotateAntimicrobial Agents and Chemotherapy, 1993
- Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution techniqueAntimicrobial Agents and Chemotherapy, 1979